Vertex continues its march into neuromuscular diseases with Affinia deal

Vertex is diving deeper into genetic therapies for neuromuscular diseases through an $80 million deal with Affinia to develop new AAV vectors for the indications.

Affinia Therapeutics will receive $80 million in up front and near-term milestone payments, plus milestones and tiered royalties that could bring the total to over $1.6 billion. In exchange, the company will discover AAV capsids for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) with specific properties using its AAVSmartLibrary...